Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
Immunotherapy
Current State of Combination Therapy for Checkpoint Inhibitors
Despite the clinical success of combination therapy with immune checkpoint inhibitors many research questions still remain.
Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Phase 1 RCC Vaccine Is Safe, But Lacks Clinical Response
RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
Statistical Index Suggests That Many ICI Trials Show Uncertain Clinical Benefit
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
Industry-Funded Study Suggests There Is No Association Between TCI Use and Increased Skin Cancer Risk in Atopic Dermatitis
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
Immunotherapy in mCRPC: Teasing Out the Right Dosing Schedule
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
-
Loading...
-
Loading...
Next post in Prostate Cancer
